膜杰作
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax
> 【NKG2A】
NKG2A信息
英文名称：NK cell lectin-like receptor subfamily C member 1
中文名称：自然杀伤细胞凝集素样受体亚家族C成员1
靶点别称：CD159a，NKG2A，KLRC1，Killer Cell Lectin Like Receptor C1，Killer Cell Lectin-Like Receptor Subfamily C， Member 1，CD159 Antigen-Like Family Member A，NKG2-1/B Activating NK Receptor，NKG2-A/B-Activating NK Receptor，NK Cell Receptor A，NKG2-A/NKG2-B Type II Integral Membrane Protein，NKG2-A/B Type II Integral Membrane Protein，Natural Killer Group Protein 2，Natural Killer Cell Lectin，C-Lectin Type II Protein，CD159a Antigen，NKG2，NKG2-B，NKG2-A
中文名称：自然杀伤细胞凝集素样受体亚家族C成员1
靶点别称：CD159a，NKG2A，KLRC1，Killer Cell Lectin Like Receptor C1，Killer Cell Lectin-Like Receptor Subfamily C， Member 1，CD159 Antigen-Like Family Member A，NKG2-1/B Activating NK Receptor，NKG2-A/B-Activating NK Receptor，NK Cell Receptor A，NKG2-A/NKG2-B Type II Integral Membrane Protein，NKG2-A/B Type II Integral Membrane Protein，Natural Killer Group Protein 2，Natural Killer Cell Lectin，C-Lectin Type II Protein，CD159a Antigen，NKG2，NKG2-B，NKG2-A
上市药物数量：0
临床药物数量：1
最高研发阶段：临床三期
临床药物数量：1
最高研发阶段：临床三期
NKG2A产品列表
产品库
属性
| 货号 | 物种 | 产品描述 | 蛋白结构 | 纯度 | 活性 |
|---|---|---|---|---|---|
| NKA-H5244 |
 Human |
Human NKG2A / CD159a Protein, His Tag |
 |
  |
|
| NKA-H526c |
Human |
Human NKG2A / CD159a Protein, Fc Tag |
 |
 |
|
| NKA-C5245 |
 Cynomolgus |
Cynomolgus NKG2A / CD159a Protein, His Tag |
 |
 |
|
| NKA-M52H5 |
 Mouse |
Mouse NKG2A / CD159a Protein, His Tag |
 |
 |
评论(1)
NKA-C5245|Cynomolgus NKG2A / CD159a Protein, His Tag
- 156XXXXXXX8
- 我们采购这个蛋白进行小鼠免疫，后期筛选能够结合猴源NKG2A蛋白的鼠源抗体分子。蛋白入库后，我们进行了纯度检测，纯度能够满足免疫要求。
- 2022-06-29
0人赞
NKG2A 分子别名
NKG2A,CD159a,KLRC1,NK cell receptor A
NKG2A 分子背景
NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation, also known as KLRC1, CD159a, NK cell receptor A and NKG2-A/NKG2-B type II integral membrane protein. NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors. NKG2A blockade therapy operated through CD8 T cells, but not NK cells. The increase in NKG2A expression might be induced by IL-10, which was present at a high level in the plasma of HCC patients. Blocking IL-10 could specifically inhibit NKG2A expression in NK cells. These findings indicate that NKG2A expression is influenced by factors from cancer nests and contributes to NK cell exhaustion, suggesting that NKG2A blockade has the potential to restore immunity against liver tumors by reversing NK cell exhaustion.
